1262989-52-5Relevant academic research and scientific papers
GPR40 AGONISTS
-
Paragraph 00299; 00300, (2020/12/11)
This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
Boron-Containing Small Molecules as Anti-Inflammatory Agents
-
Paragraph 1196, (2015/11/16)
Compounds and methods of treating anti-inflammatory conditions are disclosed.
BORON-CONTAINING SMALL MOLECULES
-
Page/Page column 148, (2011/08/21)
Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.
